Following last year's wide-ranging Chantix recall, Pfizer is initiating another product pull thanks to higher-than-allowed levels of a likely carcinogen.
A trio of companies have issued separate voluntary recalls for treatments of heart disease, diabetes and dermatitis, according to details posted on FDA’s website. The recalls were due to possible device delivery failure, stability of product and the presence of bacteria.
China's Hansoh Pharma inked two siRNA partnerships. Johnson & Johnson intends to roll out a tailored patient support program for Legend Biotech's upcoming CAR-T therapy. Brii Biosciences' COVID-19 antibody combo could be a blockbuster opportunity, one analyst said. And more.
Thyroid Tablets From Acella Pharmaceuticals Get Major Recall for Lack of Potency
On 5/2/21 at 11:45 PM EDT
People taking thyroid medications from Acella Pharmaceuticals have been warned that the company has recalled 35 commercial lots of its tablets for a lack of potency, according to the United Stated Food and Drug Administration (FDA).
Patients who take these tablets for underactive thyroids will not get the full potency or less than the 90 percent on its label, the FDA stated on its website this weekend.
Those who take the medication can experience these symptoms: hypothyroidism (underactive thyroid) which may include, fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight.